April 13, 2021 8:17am
MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.
Biostage (BSTG) closed down Monday -$0.08 to $1.17 with 3,631 shares traded after Friday’s flat at $1.25 with 260 shares traded, Thursday with 6 shares traded, Wednesday’s $1.25 with 967 shares traded and last Tuesday’s -$0.05 to $1.25 with 2008 shares traded
Question#1: HOW many executives or management “team members” remain at the company? Is the website truthful and up-to-date regarding those WHO have left for other positions?
Question2: WHO is in charge of clinical and pre-clinical development?
Question#3: WHAT is behind the volatility and daily volume relationship and WHO is “propping” the share pricing (review the differences). Shouldn’t RSM US LLP review the relationship with DST Capital and Hong Yu, president of BSTG?